Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Immune Globulin Intravenous, Human
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : GC Biopharma
Deal Size : Undisclosed
Deal Type : Partnership
Soleo Health Selected as Specialty Pharmacy for ALYGLO™ for Adults with PI
Details : Soleo partnership with GC Biopharma to dispense Alyglo (Immune Globulin Intravenous, Human-stwk) 10% Liquid for treating Adults with Primary Humoral Immunodeficiency.
Brand Name : Alyglo
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 16, 2024
Lead Product(s) : Immune Globulin Intravenous, Human
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : GC Biopharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Inclisiran
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Soleo Health Selected by Novartis as Limited Drug Distribution Partner for Administration of LEQVIO
Details : LEQVIO (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH).
Brand Name : Leqvio
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 26, 2022
Lead Product(s) : Inclisiran
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Mitsubishi Tanabe Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Specialty pharmacy partners to dispense nationwide RADICAVA ORS® (edaravone) oral suspension, commercialized by Mitsubishi Tanabe Pharma America, Inc. (MTPA), which commercializes approved pharmaceutical products in North America.
Brand Name : Radicava ORS
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 07, 2022
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Mitsubishi Tanabe Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Efgartigimod
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Argenx
Deal Size : Undisclosed
Deal Type : Partnership
Soleo Health Selected as Limited Distribution Partner for VYVGART™
Details : Soleo Health offers differentiated capabilities through its ability to collect real-world data and generate intelligent outcomes from VYVGART patients with its exclusive and proprietary clinical outcomes program, SoleMetrics®.
Brand Name : Vyvgart
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 24, 2022
Lead Product(s) : Efgartigimod
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Argenx
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Immune globulin human-klhw
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Grifols International
Deal Size : Undisclosed
Deal Type : Agreement
Soleo Health Selected by Grifols as Limited Drug Distribution Partner for XEMBIFY®
Details : Soleo Health was chosen as a limited distributor of XEMBIFY. This is Grifols’ first 20% immune globulin.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 01, 2020
Lead Product(s) : Immune globulin human-klhw
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Grifols International
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?